DSIP vs Epithalon

DSIP was isolated from rabbit cerebral venous blood in 1977 and proposed as a sleep factor, but a 2006 review notes that no gene, precursor protein or receptor has been identified and that the sleep hypothesis remains weakly documented ⁵. In animals (dogs, rats and a monkey), its half-life after intravenous dosing was a few minutes, and it is broken down quickly by blood peptidases ¹.

Human data are small and mixed. A double-blind placebo-controlled study in 14 people with severe chronic insomnia reported improved night sleep and daytime alertness ⁶. A double-blind study in 16 people with chronic insomnia found only weak effects that may have reflected changes in the placebo group, and the authors judged a major therapeutic effect unlikely ⁷. In its 2026 review, the FDA concluded that the insomnia evidence was inconclusive and that there were no safety data for the subcutaneous route ¹.

Epithalon was synthesised from the amino-acid composition of epithalamin, a bovine pineal extract, and much of the literature comes from the group that developed it ^2,9. In human fetal fibroblast cultures (cell data), it induced telomerase expression and activity and lengthened telomeres ⁸. A 2025 review summarises cell, animal and computational work reporting effects on melatonin synthesis, enzyme activity and immune-cell markers, while noting that its mechanisms remain uncertain ⁹.

The FDA's 2026 review found no studies of epitalon in people with insomnia, no pharmacokinetic data and no human safety data ². It also noted that available mouse toxicology studies were too limited to inform cancer risk, which it considered relevant because epitalon activates telomerase ².